Karl-Anton Kreuzer

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo et al. · New England Journal of Medicine · 2019 · 852 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Kirsten Fischer, Jasmin Bahlo, Anna Maria Fink et al. · Blood · 2015 · 700 citations · Full text

Life Sciences, Immunology, Oncology +8

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Othman Al‐Sawaf, Can Zhang, Maneesh Tandon et al. · The Lancet Oncology · 2020 · 327 citations

Medicine, Hematology, Immunology +15

Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse

Manoj Garg, Yasunobu Nagata, Deepika Kanojia et al. · Blood · 2015 · 216 citations · Full text

Medicine, Hematology, Oncology +14

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

Guillermo Garcia‐Manero, Pierre Fenaux, Aref Al‐Kali et al. · The Lancet Oncology · 2016 · 171 citations

Medicine, Pharmacotherapy, Clinical Pharmacology +6